|
1
|
El-Serag HB: Epidemiology of viral
hepatitis and hepatocellular carcinoma. Gastroenterology.
142:1264–1273.e1. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al SHARP Investigators Study Group: Sorafenib in advanced
hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Schmidt-Wolf IG, Lefterova P, Mehta BA,
Fernandez LP, Huhn D, Blume KG, Weissman IL and Negrin RS:
Phenotypic characterization and identification of effector cells
involved in tumor cell recognition of cytokine-induced killer
cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
|
|
4
|
Wang FS, Liu MX, Zhang B, Shi M, Lei ZY,
Sun WB, Du QY and Chen JM: Antitumor activities of human autologous
cytokine-induced killer (CIK) cells against hepatocellular
carcinoma cells in vitro and in vivo. World J Gastroenterol.
8:464–468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim HM, Lim J, Yoon YD, Ahn JM, Kang JS,
Lee K, Park SK, Jeong YJ, Kim JM, Han G, et al: Anti-tumor activity
of ex vivo expanded cytokine-induced killer cells against human
hepatocellular carcinoma. Int Immunopharmacol. 7:1793–1801. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lu PH and Negrin RS: A novel population of
expanded human CD3+CD56+ cells derived from T
cells with potent in vivo antitumor activity in mice with severe
combined immunodeficiency. J Immunol. 153:1687–1696.
1994.PubMed/NCBI
|
|
7
|
Nishimura R, Baker J, Beilhack A, Zeiser
R, Olson JA, Sega EI, Karimi M and Negrin RS: In vivo trafficking
and survival of cytokine-induced killer cells resulting in minimal
GVHD with retention of antitumor activity. Blood. 112:2563–2574.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baker J, Verneris MR, Ito M, Shizuru JA
and Negrin RS: Expansion of cytolytic CD8(+) natural killer T cells
with limited capacity for graft-versus-host disease induction due
to interferon gamma production. Blood. 97:2923–2931. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Olioso P, Giancola R, Di Riti M, Contento
A, Accorsi P and Iacone A: Immunotherapy with cytokine induced
killer cells in solid and hematopoietic tumours: A pilot clinical
trial. Hematol Oncol. 27:130–139. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Shi M, Zhang B, Tang ZR, Lei ZY, Wang HF,
Feng YY, Fan ZP, Xu DP and Wang FS: Autologous cytokine-induced
killer cell therapy in clinical trial phase I is safe in patients
with primary hepatocellular carcinoma. World J Gastroenterol.
10:1146–1151. 2004.PubMed/NCBI
|
|
11
|
Hao MZ, Lin HL, Chen Q, Ye YB, Chen QZ and
Chen MS: Efficacy of transcatheter arterial chemoembolization
combined with cytokine-induced killer cell therapy on
hepatocellular carcinoma: a comparative study. Chin J Cancer.
29:172–177. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu
FM, He N, Pan CC, Xia JC, Wu PH and Zhao M: Cytokine-induced killer
cells in combination with transcatheter arterial chemoembolization
and radiofrequency ablation for hepatocellular carcinoma patients.
J Immunother. 36:287–293. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pan K, Li YQ, Wang W, Xu L, Zhang YJ,
Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, et al: The efficacy of
cytokine-induced killer cell infusion as an adjuvant therapy for
postoperative hepatocellular carcinoma patients. Ann Surg Oncol.
20:4305–4311. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui J, Wang N, Zhao H, Jin H, Wang G, Niu
C, Terunuma H, He H and Li W: Combination of radiofrequency
ablation and sequential cellular immunotherapy improves
progression-free survival for patients with hepatocellular
carcinoma. Int J Cancer. 134:342–351. 2014. View Article : Google Scholar
|
|
15
|
Weng DS, Zhou J, Zhou QM, Zhao M, Wang QJ,
Huang LX, Li YQ, Chen SP, Wu PH and Xia JC: Minimally invasive
treatment combined with cytokine-induced killer cells therapy lower
the short-term recurrence rates of hepatocellular carcinomas. J
Immunother. 31:63–71. 2008. View Article : Google Scholar
|
|
16
|
Yu X, Zhao H, Liu L, Cao S, Ren B, Zhang
N, An X, Yu J, Li H and Ren X: A randomized phase II study of
autologous cytokine-induced killer cells in treatment of
hepatocellular carcinoma. J Clin Immunol. 34:194–203. 2014.
View Article : Google Scholar
|
|
17
|
Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ,
Yu SJ, Gwak GY, Kim KM, Lee JW and Yoon JH: Adjuvant immunotherapy
with autologous cytokine-induced killer cells for hepatocellular
carcinoma. Gastroenterology. 148:1383–1391.e6. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takayama T, Sekine T, Makuuchi M, Yamasaki
S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi
Y and Kakioze T: Adoptive immunotherapy to lower postsurgical
recurrence rates of hepatocellular carcinoma: A randomised trial.
Lancet. 356:802–807. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li X, Dai D, Song X, Liu J, Zhu L and Xu
W: A meta-analysis of cytokine-induced killer cells therapy in
combination with minimally invasive treatment for hepatocellular
carcinoma. Clin Res Hepatol Gastroenterol. 38:583–591. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Leboeuf C, Mailly L, Wu T, Bour G, Durand
S, Brignon N, Ferrand C, Borg C, Tiberghien P, Thimme R, et al: In
vivo proof of concept of adoptive immunotherapy for hepatocellular
carcinoma using allogeneic suicide gene-modified killer cells. Mol
Ther. 22:634–644. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ciceri F, Bonini C, Marktel S, Zappone E,
Servida P, Bernardi M, Pescarollo A, Bondanza A, Peccatori J,
Rossini S, et al: Antitumor effects of HSV-TK-engineered donor
lymphocytes after allogeneic stem-cell transplantation. Blood.
109:4698–4707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Deschamps M, Mercier-Lethondal P, Certoux
JM, Henry C, Lioure B, Pagneux C, Cahn JY, Deconinck E, Robinet E,
Tiberghien P and Ferrand C: Deletions within the HSV-tk transgene
in long-lasting circulating gene-modified T cells infused with a
hematopoietic graft. Blood. 110:3842–3852. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou X, Di Stasi A, Tey SK, Krance RA,
Martinez C, Leung KS, Durett AG, Wu MF, Liu H, Leen AM, et al:
Long-term outcome after haploidentical stem cell transplant and
infusion of T cells expressing the inducible caspase 9 safety
transgene. Blood. 123:3895–3905. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tiberghien P, Ferrand C, Lioure B, Milpied
N, Angonin R, Deconinck E, Certoux JM, Robinet E, Saas P, Petracca
B, et al: Administration of herpes simplex-thymidine
kinase-expressing donor T cells with a T-cell-depleted allogeneic
marrow graft. Blood. 97:63–72. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bonini C, Ferrari G, Verzeletti S, Servida
P, Zappone E, Ruggieri L, Ponzoni M, Rossini S, Mavilio F,
Traversari C and Bordignon C: HSV-TK gene transfer into donor
lymphocytes for control of allogeneic graft-versus-leukemia.
Science. 276:1719–1724. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Di Stasi A, Tey SK, Dotti G, Fujita Y,
Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG,
Grilley B, et al: Inducible apoptosis as a safety switch for
adoptive cell therapy. N Engl J Med. 365:1673–1683. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhou X, Dotti G, Krance RA, Martinez CA,
Naik S, Kamble RT, Durett AG, Dakhova O, Savoldo B, Di Stasi A, et
al: Inducible caspase-9 suicide gene controls adverse effects from
alloreplete T cells after haploidentical stem cell transplantation.
Blood. 125:4103–4113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ott PA, Herzog BA, Quast S, Hofstetter HH,
Boehm BO, Tary-Lehmann M, Durinovic-Bello I, Berner BR and Lehmann
PV: Islet-cell antigen-reactive T cells show different expansion
rates and Th1/Th2 differentiation in type 1 diabetic patients and
healthy controls. Clin Immunol. 115:102–114. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Imataki O, Heike Y, Makiyama H, Iizuka A,
Ikarashi Y, Ishida T, Wakasugi H and Takaue Y: Insufficient ex vivo
expansion of Valpha24(+) natural killer T cells in malignant
lymphoma patients related to the suppressed expression of CD1d
molecules on CD14(+) cells. Cytotherapy. 10:497–506. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vickers MA, Wilkie GM, Robinson N, Rivera
N, Haque T, Crawford DH, Barry J, Fraser N, Turner DM, Robertson V,
et al: Establishment and operation of a good manufacturing
practice-compliant allogeneic Epstein-Barr virus (EBV)-specific
cytotoxic cell bank for the treatment of EBV-associated
lymphoproliferative disease. Br J Haematol. 167:402–410. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Robinet E, Certoux JM, Ferrand C, Maples
P, Hardwick A, Cahn JY, Reynolds CW, Jacob W, Hervé P and
Tiberghien P: A closed culture system for the ex vivo transduction
and expansion of human T lymphocytes. J Hematother. 7:205–215.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tey SK, Dotti G, Rooney CM, Heslop HE and
Brenner MK: Inducible caspase 9 suicide gene to improve the safety
of allodepleted T cells after haploidentical stem cell
transplantation. Biol Blood Marrow Transplant. 13:913–924. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kühlcke K, Ayuk FA, Li Z, Lindemann C,
Schilz A, Schade UM, Fauser AA, Zander AR, Eckert HG and Fehse B:
Retroviral transduction of T lymphocytes for suicide gene therapy
in allogeneic stem cell transplantation. Bone Marrow Transplant.
25(Suppl 2): S96–S98. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mercier-Letondal P, Montcuquet N, Sauce D,
Certoux JM, Jeanningros S, Ferrand C, Bonyhadi M, Tiberghien P and
Robinet E: Alloreactivity of ex vivo-expanded T cells is correlated
with expansion and CD4/CD8 ratio. Cytotherapy. 10:275–288. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sauce D, Tonnelier N, Duperrier A,
Petracca B, de Carvalho Bittencourt M, Saadi M, Saas P, Ferrand C,
Herve P, Tiberghien P and Robinet E: Influence of ex vivo expansion
and retrovirus-mediated gene transfer on primary T lymphocyte
phenotype and functions. J Hematother Stem Cell Res. 11:929–940.
2002. View Article : Google Scholar
|
|
36
|
Fehse B, Kustikova OS, Li Z, Li Z, Wahlers
A, Bohn W, Beyer WR, Chalmers D, Tiberghien P, Kühlcke K, Zander AR
and Baum C: A novel 'sort-suicide' fusion gene vector for T cell
manipulation. Gene Ther. 9:1633–1638. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chan JK, Hamilton CA, Cheung MK, Karimi M,
Baker J, Gall JM, Schulz S, Thorne SH, Teng NN, Contag CH, et al:
Enhanced killing of primary ovarian cancer by retargeting
autologous cytokine-induced killer cells with bispecific
antibodies: A preclinical study. Clin Cancer Res. 12:1859–1867.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi Y, Wu W, Wan T, Liu Y, Peng G, Chen Z
and Zhu H: Impact of polyclonal anti-CD3/CD28-coated magnetic bead
expansion methods on T cell proliferation, differentiation and
function. Int Immunopharmacol. 15:129–137. 2013. View Article : Google Scholar
|
|
39
|
Rutella S and Locatelli F: Is there a role
for cytokine-induced killer cells in cancer immunotherapy?
Immunotherapy. 4:867–869. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Straathof KC, ulè MA, Yotnda P, Dotti G,
Vanin EF, Brenner MK, Heslop HE, Spencer DM and Rooney CM: An
inducible caspase 9 safety switch for T-cell therapy. Blood.
105:4247–4254. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Marin V, Cribioli E, Philip B, Tettamanti
S, Pizzitola I, Biondi A, Biagi E and Pule M: Comparison of
different suicide-gene strategies for the safety improvement of
genetically manipulated T cells. Hum Gene Ther Methods. 23:376–386.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Rajbhandary S, Zhao MF, Zhao N, Lu WY, Zhu
HB, Xiao X, Deng Q and Li YM: Multiple cytotoxic factors involved
in IL-21 enhanced antitumor function of CIK cells signaled through
STAT-3 and STAT5b pathways. Asian Pac J Cancer Prev. 14:5825–5831.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Hu L, Cao D, Li Y, He Y and Guo K:
Resveratrol sensitized leukemia stem cell-like KG-1a cells to
cytokine-induced killer cells-mediated cytolysis through NKG2D
ligands and TRAIL receptors. Cancer Biol Ther. 13:516–526. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Franceschetti M, Pievani A, Borleri G,
Vago L, Fleischhauer K, Golay J and Introna M: Cytokine-induced
killer cells are terminally differentiated activated CD8 cytotoxic
T-EMRA lymphocytes. Exp Hematol. 37:616–628. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Haque T, Wilkie GM, Taylor C, Amlot PL,
Murad P, Iley A, Dombagoda D, Britton KM, Swerdlow AJ and Crawford
DH: Treatment of Epstein-Barr-virus-positive post-transplantation
lymphoproliferative disease with partly HLA-matched allogeneic
cytotoxic T cells. Lancet. 360:436–442. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Haque T, Wilkie GM, Jones MM, Higgins CD,
Urquhart G, Wingate P, Burns D, McAulay K, Turner M, Bellamy C, et
al: Allogeneic cytotoxic T-cell therapy for EBV-positive
post-transplantation lymphoproliferative disease: results of a
phase 2 multicenter clinical trial. Blood. 110:1123–1131. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Slavin S, Ackerstein A, Or R, Shapira MY,
Gesundheit B, Askenasy N and Morecki S: Immunotherapy in high-risk
chemotherapy-resistant patients with metastatic solid tumors and
hematological malignancies using intentionally mismatched donor
lymphocytes activated with rIL-2: A phase I study. Cancer Immunol
Immunother. 59:1511–1519. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Contassot E, Robinet E, Angonin R,
Laithier V, Bittencourt M, Pavy JJ, Cahn JY, Hervé P and Tiberghien
P: Differential effects of cyclosporin A on the alloreactivity of
fresh and ex vivo-expanded T lymphocytes. Bone Marrow Transplant.
22:1097–1102. 1998. View Article : Google Scholar
|
|
49
|
Maury S, Litvinova E, Boyer O, Benard L,
Bruel S, Klatzmann D and Cohen JL: Effect of combined cytostatic
cyclosporin A and cytolytic suicide gene therapy on the prevention
of experimental graft-versus-host disease. Gene Ther. 9:201–207.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Dudley ME, Wunderlich JR, Yang JC, Sherry
RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE,
Mavroukakis SA, et al: Adoptive cell transfer therapy following
non-myeloablative but lymphodepleting chemotherapy for the
treatment of patients with refractory metastatic melanoma. J Clin
Oncol. 23:2346–2357. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ghiringhelli F, Menard C, Puig PE, Ladoire
S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L and Chauffert
B: Metronomic cyclophosphamide regimen selectively depletes
CD4+CD25+ regulatory T cells and restores T
and NK effector functions in end stage cancer patients. Cancer
Immunol Immunother. 56:641–648. 2007. View Article : Google Scholar
|
|
52
|
Zhang JF, Liu JJ, Lu MQ, Cai CJ, Yang Y,
Li H, Xu C and Chen GH: Rapamycin inhibits cell growth by induction
of apoptosis on hepatocellular carcinoma cells in vitro. Transpl
Immunol. 17:162–168. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Semela D, Piguet AC, Kolev M, Schmitter K,
Hlushchuk R, Djonov V, Stoupis C and Dufour JF: Vascular remodeling
and antitumoral effects of mTOR inhibition in a rat model of
hepatocellular carcinoma. J Hepatol. 46:840–848. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Martin A, Tisch RM and Getts DR:
Manipulating T cell-mediated pathology: Targets and functions of
monoclonal antibody immunotherapy. Clin Immunol. 148:136–147. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Waldmann H, Adams E and Cobbold S:
Reprogramming the immune system: Co-receptor blockade as a paradigm
for harnessing tolerance mechanisms. Immunol Rev. 223:361–370.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fife BT and Bluestone JA: Control of
peripheral T-cell tolerance and autoimmunity via the CTLA-4 and
PD-1 pathways. Immunol Rev. 224:166–182. 2008. View Article : Google Scholar : PubMed/NCBI
|
